In a groundbreaking move, Merck, a global leader in science and technology, announced the launch of AIDDISON™, the first-ever software-as-a-service platform designed to revolutionize the pharmaceutical industry by integrating drug discovery and synthesis. This innovative solution marks a significant leap in the field of drug development, promising to enhance the efficiency and success rates of new drugs and therapies.
AIDDISON™ stands out as a unique convergence of generative AI, machine learning, and computer-aided drug design. This powerful combination allows for the virtual screening of compounds from an expansive universe of over 60 billion chemical targets. The software evaluates potential synthesis routes, aiming for safer, cost-effective, and higher-yield drug manufacturing.
The Researchers Leaving Meta, And Where They’re Headed
Mukundan Sivaraj
